Lead Product(s) : Pulmobiotics Engineered Live Biotherapeutic
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pulmobiotics’ engineered live biotherapeutic significantly reduced antibiotic-resistant pseudomonas aeruginosa infections in the lungs of mice, improving survival rates, and dissolved biofilms formed on endotracheal tubes of patients with VAP.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 19, 2023
Lead Product(s) : Pulmobiotics Engineered Live Biotherapeutic
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MVT-201
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inmunomet Intolerancia y Disbiosis SL
Deal Size : $1.6 million
Deal Type : Financing
Details : Microviable will use the seed funding to enhance their therapeutic development platform and advance their pipeline to the clinical stage, including lead product, MVT-201, at pre-clinical stage with positive results, and it is an unique biological drug fo...
Product Name : MVT-201
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
April 19, 2022
Lead Product(s) : MVT-201
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inmunomet Intolerancia y Disbiosis SL
Deal Size : $1.6 million
Deal Type : Financing
Lead Product(s) : Antithrombin III
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Endpoint Health
Deal Size : $25.0 million
Deal Type : Collaboration
Details : As part of the agreement, Grifols will contribute its industry-leading expertise in plasma-protein therapies and be the exclusive supplier of Antithrombin III (AT-III), a plasma protein that treats patients with blood clotting issues.
Product Name : AT-III
Product Type : Protein
Upfront Cash : Undisclosed
February 24, 2022
Lead Product(s) : Antithrombin III
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Endpoint Health
Deal Size : $25.0 million
Deal Type : Collaboration
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pharma Mar has obtained MHRA approval for UK patients to participate in the Phase III NEPTUNO clinical trial, which will determine the efficacy of Aplidin® for the treatment of hospitalized patients with moderate COVID-19 infection.
Product Name : Aplidin
Product Type : Peptide
Upfront Cash : Inapplicable
February 17, 2021
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In vitro experiments confirmed inhibition of the protease with an IC50 in the low micromolar range. Eravacycline inhibits the infection of SARS-CoV-2 in VeroE6 cells and shows no toxicity when applied alone.
Product Name : TP-434
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 19, 2020
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PharmaMar reports positive results for Aplidin® against coronavirus HCoV-229E
Details : PharmaMar will contact regulatory authorities to analyze the possibilities of studies on patients infected with Covid-19.
Product Name : Aplidin
Product Type : Peptide
Upfront Cash : Inapplicable
March 13, 2020
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable